The Swiss HIV Cohort Study - Multifaceted network supporting patient care as well as large international research projects;Die Schweizerische HIV-kohortenstudie - Ein netzwerk gespannt zwischen individueller patienten-betreuung und internationaler forschungs-zusammenarbeit

Therapeutische Umschau

Volumn 61, Issue 10, 2004, Pages 635-638

  Flepp, Markus ^a   Ledergerber, B ^b  

^a KLINIK IM PARK   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COHORT ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNATIONAL COOPERATION; LEGAL ASPECT; MEDICAL SPECIALIST; PATIENT CARE; REVIEW; SOCIAL PSYCHOLOGY; STANDARD; SWITZERLAND; UNIVERSITY HOSPITAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; BIOMEDICAL RESEARCH; CLINICAL TRIALS; COHORT STUDIES; DATABASES; HIV INFECTIONS; HUMANS; INTERNATIONAL COOPERATION; MULTICENTER STUDIES; PROSPECTIVE STUDIES; QUALITY ASSURANCE, HEALTH CARE; SWITZERLAND;

EID: 7044249285     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930.61.10.635     Document Type: Review

References (8)

1. Kirk O, Mocroft A, Katzenstein TL et al. Changes in use of antiretroviral therapy in regions of Europe over time. EuroSIDA Study Group. AIDS 1998; 12: 2031-9.
2. Friis-Moller N, Sabin CA, Weber R et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
3. CASCADE Collaboration. Changes in the uptake of antiretroviral therapy nd survival in people with known duration of HIV infection in Europe: results from CASCADE. HIV Med 2000; 1: 224-31.
4. Egger M, May M, Chene G et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 119-29.
5. Ledergerber B, Mocroft A, Reiss P et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. N Engl J Med 2001; 344: 168-74.
6. Kirk O, Reiss P, Uberti-Foppa C et al. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med 2002; 137: 239-50.
7. Phillips AN, Staszewski S, Weber R et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA 2001; 286: 2560-7.
8. Ledergerber B, Lundgren JD, Walker AS et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virologic failure to all three antiretroviral-drug classes. Lancet 2004; in press.